Study on Crohn’s Disease Treatment in Older Patients

Background on Crohn’s Disease

A recent study investigated the safety and effectiveness of early combined immunosuppression compared to conventional treatment in older patients diagnosed with Crohn’s disease. Crohn’s disease and ulcerative colitis are the primary forms of inflammatory bowel disease (IBD), a chronic inflammatory condition affecting the gastrointestinal tract. Traditionally thought to primarily affect younger individuals, recent data indicate that 10-30% of IBD patients are over the age of 60, either developing the disease late in life or living with it as they age.

Comparison of Treatment Approaches

The management of Crohn’s disease aims to achieve three essential goals: inducing and maintaining remission, enhancing quality of life, and preventing complications to minimize adverse effects. The conventional treatment typically involves corticosteroids, which can help manage symptoms. However, prolonged use may lead to steroid resistance or dependency, and increased mortality risk is associated with extended corticosteroid exposure.

An alternative treatment strategy employs combined immunosuppressant therapy, which utilizes biologic agents such as anti-tumor necrosis factor alongside immunosuppressive agents like thiopurines.

Clinical Challenges in Older Patients

Several studies have highlighted the complexities involved in diagnosing and treating Crohn’s disease in older patients. Diagnosing this condition can be challenging due to age-related physical changes, coexisting medical conditions, and atypical symptom presentations.

Adverse events can limit treatment options for older patients, and the presence of multiple comorbidities complicates therapy. The risk of drug interactions increases due to polypharmacy, and the lack of efficacy trials specifically for older adults restricts physicians in exploring various treatment methods.

Preferred Therapy in Younger Patients

In younger patients, physicians often employ a combination of biologics and anti-metabolites as an aggressive treatment strategy, particularly for those at high risk of complications. However, the safety and effectiveness of such aggressive therapies in older patients remain unverified. Consequently, conventional corticosteroid treatment is commonly preferred for older individuals with Crohn’s disease.

New Study Findings on Combined Immunosuppression

Research Overview

Researchers from the University of California San Diego conducted a study that compared early combined immunosuppression with conventional treatment among older patients as part of a post hoc analysis of the randomized evaluation for Crohn’s treatment (REACT) trial. The results were published in the journal Alimentary Pharmacology & Therapeutics.

The trial involved 1,981 patients, with 311 aged 60 years or older. The researchers assessed the impact of age on the risk of adverse events linked to early combined immunosuppression compared to conventional management. From the study, 173 patients were assigned to early combined therapy while 138 were placed on conventional treatment. Patients who did not achieve clinical remission within 4-12 weeks of conventional treatment received a combination therapy that included anti-tumor necrosis factor and an antimetabolite.

Results of the Study

The study monitored adverse events, including Crohn’s disease-related hospitalizations, surgeries, and other complications, while also measuring safety outcomes in older versus younger patients. Follow-up lasted for 24 months, during which 10% of older patients experienced complications related to Crohn’s disease—6.4% in the combined treatment group and 14.5% in the conventional treatment group.

The analysis revealed no significant differences in the effectiveness of early combined treatment based on anti-tumor necrosis factor between older and younger patients. Moreover, there was no increase in side effects among the older cohort. Although a higher number of older patients succumbed to Crohn’s disease compared to younger patients, mortality rates did not differ between the conventional and combined treatment groups in older patients.

Implications of the Findings

A key strength of the study lies in its post hoc analysis of a cluster randomized trial, allowing for broader applicability of the findings. The extended follow-up period facilitated a thorough assessment of the risk of Crohn’s disease-related complications. However, certain limitations exist, such as the exploratory nature of the results and the inability to evaluate long-term effectiveness and safety of the treatment strategies.

Conclusions on Immunosuppression for Older Patients

The study’s findings suggest that early combined immunosuppression therapy utilizing anti-tumor necrosis factor can be both safe and effective for older patients, similar to its performance in younger patients. This treatment option may provide a viable alternative to the chronic use of corticosteroids in older individuals. The researchers recommend that future studies should focus on identifying optimal treatment approaches for older patients at a heightened risk of Crohn’s disease complications.

Reference

Sidharth Singh et al., Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019;1-7. DOI:10.1111/apt.15214.